The biotech company CONNECTA Therapeutics, a member of CATALONIA.HEALTH, has announced positive results from its Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics profile of its drug candidate CTH120 in adult volunteers.
CTH120 is an investigational drug that modulates neuroplasticity, a property of the brain affected in many neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), Down syndrome and Fragile X syndrome (FXS). CONNECTA’s randomised, double-blind, placebo-controlled, Phase I clinical trial recruited 76 healthy adults (men and women aged 18 to 55) at Hospital del Mar Research Institute (HMRI) in Barcelona.
CONNECTA Therapeutics is currently conducting an observational study on the biomarkers that will be used in the Phase IIa clinical trial with Hospital del Mar Research Institute (HMRI), the Parc Taulí Research and Innovation Institute (I3PT), both members of CATALONIA.HEALTH, and the Centre for Genomic Regulation.
Josep Prous, Co-Founder and Chief Scientific Officer of CONNECTA Therapeutics, commented, “the results are very solid and encourage us to evaluate the efficacy of CTH120 in adults with FXS in Phase II clinical trials, starting in the second half of 2025.”
Jordi Fàbrega, Co-Founder and CEO of CONNECTA Therapeutics, concluded, “We’re very pleased to move forward the clinical development of CTH120 and excited that our investigational drugs may improve the quality of life for patients with neurodevelopmental disorders and their families, currently a high unmet medical need”.
Comments